surmount 1 tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial SURMOUNT-1: Tirzepatide Drastically Reduces Weight – Tirzepatide lowers body weight for

The clinical development program is one of the largest trial programs for the management of obesity

Drug interactions are relatively uncommon with Rybelsus, but because it slows gastric emptying, it may affect the absorption of other oral medications

Postmenopausal women werent well represented

Conclusion Under real-life conditions, lack of persistence in treatment with GLP-1RA among type 2 diabetes adults with obesity remains a significant concern, particularly since those who were persistent showed improved glycaemic control as compared with non-persistent patients

Patients curious about it should hear from a physician about what is actually known and what is not